Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 12Observational 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion 1Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × larotrectinib × 1 year × Clear all
NCT04142437 2026-04-14

ON-TRK

Bayer

Recruiting
150 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

NCT04945330 2026-04-14

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Bayer

Recruiting
100 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡